IN2014MN01962A - - Google Patents

Info

Publication number
IN2014MN01962A
IN2014MN01962A IN1962MUN2014A IN2014MN01962A IN 2014MN01962 A IN2014MN01962 A IN 2014MN01962A IN 1962MUN2014 A IN1962MUN2014 A IN 1962MUN2014A IN 2014MN01962 A IN2014MN01962 A IN 2014MN01962A
Authority
IN
India
Prior art keywords
cabazitaxel
crystalline form
preparation
novel
novel crystalline
Prior art date
Application number
Inventor
Jing Li
Quanxing Yao
Original Assignee
Chongqing Taihao Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Taihao Pharmaceutical Co Ltd filed Critical Chongqing Taihao Pharmaceutical Co Ltd
Publication of IN2014MN01962A publication Critical patent/IN2014MN01962A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

The present invention relates to the field of medical chemistry and discloses a preparation method for three crystal forms of cabazitaxel that is ester compound crystalline form J of cabazitaxel hydrate crystalline form G of cabazitaxel and crystalline form I of cabazitaxel and a novel crystalline form of cabazitaxel. The novel crystalline form of cabazitaxel according to the invention has good stability and good solubility in commonly used solvents and is easy to be preserved and is stable under treatment during preparation of dosage forms thus could be used for the preparation of drugs for treating prostate cancer.
IN1962MUN2014 2012-07-25 2013-07-18 IN2014MN01962A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210259595.3A CN102746258B (en) 2012-07-25 2012-07-25 Crystal forms of cabazitaxel and preparation method thereof
PCT/CN2013/079575 WO2014015760A1 (en) 2012-07-25 2013-07-18 Crystal form of cabazitaxel and preparation method thereof

Publications (1)

Publication Number Publication Date
IN2014MN01962A true IN2014MN01962A (en) 2015-07-10

Family

ID=47026807

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1962MUN2014 IN2014MN01962A (en) 2012-07-25 2013-07-18

Country Status (8)

Country Link
US (1) US9353076B2 (en)
EP (2) EP2835369B1 (en)
JP (1) JP6329135B2 (en)
CN (1) CN102746258B (en)
AU (2) AU2013295924B2 (en)
CA (2) CA2870569A1 (en)
IN (1) IN2014MN01962A (en)
WO (1) WO2014015760A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023950B1 (en) 2011-04-12 2016-07-29 Тева Фармасьютикалз Интернэшнл Гмбх Solid state forms of cabazitaxel and processes for preparation thereof
CN104220431A (en) * 2012-03-08 2014-12-17 伊瓦克斯国际有限责任公司 Solid state forms of cabazitaxel and processes for preparation thereof
CN102746258B (en) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 Crystal forms of cabazitaxel and preparation method thereof
CN103804323A (en) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 Jevtana solvate and preparation method and application thereof
CN103819428B (en) * 2012-11-19 2016-01-13 齐鲁制药有限公司 Crystal formation of the solvate of 7 β, 10 β-dimethoxy docetaxel and preparation method thereof
CN103058960B (en) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 Cabazitaxel polymorphic form and preparation method thereof
KR101429543B1 (en) 2012-12-13 2014-08-14 주식회사 삼양바이오팜 A novel crystal form of cabazitaxel and a method for preparing the same
CN103044364B (en) * 2013-01-07 2016-01-20 重庆泰濠制药有限公司 Amorphous crystalline substance of a kind of Cabazitaxel and preparation method thereof
WO2014128728A2 (en) * 2013-02-25 2014-08-28 Laurus Labs Private Limited Solid forms of cabazitaxel and processes for preparation thereof
CN103450119B (en) * 2013-09-24 2015-06-17 天津炜捷制药有限公司 Cabazitaxel with crystal form W and method for preparing same
EP2865674A1 (en) * 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
CN105461665A (en) * 2014-08-21 2016-04-06 中国医学科学院药物研究所 Cabazitaxel N6 crystal form substance, and preparation method, composition and use thereof
CN105461664A (en) * 2014-08-21 2016-04-06 中国医学科学院药物研究所 Cabazitaxel N5 crystal form substance, and preparation method, composition and use thereof
JP2019501953A (en) 2016-01-15 2019-01-24 珠海貝海生物技術有限公司Ｚｈｕｈａｉ Ｂｅｉｈａｉ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Compositions and formulations comprising cabazitaxel and human serum albumin
WO2018047074A1 (en) * 2016-09-07 2018-03-15 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
CN117205305B (en) 2018-04-20 2024-04-26 珠海贝海生物技术有限公司 Formulations and compositions of cabazitaxel
CN113429369B (en) * 2021-07-23 2022-12-02 无锡紫杉药业有限公司 Efficient cabazitaxel purification method

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048610A1 (en) 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
FR2859996B1 (en) * 2003-09-19 2006-02-03 Aventis Pharma Sa ACETONIC SOLVAT OF DIMETHOXY DOCETAXEL AND PROCESS FOR PREPARING THE SAME
FR2926551A1 (en) 2008-01-17 2009-07-24 Aventis Pharma Sa CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME
CN101525321B (en) * 2008-03-06 2012-03-07 上海希迪制药有限公司 Polyenic taxusol sesquihydrate crystal and preparation method thereof
PL388144A1 (en) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate 4-acetoxy-2?-benzoiloxy-5� ,20-epoxy-1, 7�, 10�-trihydroxy-9-oxo-taks-11 -en-13?-yl solvates, a method for their production and application thereof
CN102060815B (en) * 2010-12-24 2012-09-26 重庆泰濠制药有限公司 Preparation method of taxanes compound
EA023950B1 (en) 2011-04-12 2016-07-29 Тева Фармасьютикалз Интернэшнл Гмбх Solid state forms of cabazitaxel and processes for preparation thereof
TWI526437B (en) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 Crystalline forms of cabazitaxel
US9772339B2 (en) * 2011-09-30 2017-09-26 Life Technologies Corporation Methods and systems for image analysis identification
CN102336726B (en) * 2011-09-30 2014-11-26 重庆泰濠制药有限公司 Method for preparing cabazitaxel
CN102503913B (en) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 Preparation method for dimethoxy taxanes compound monocrystal directly used for X-ray single crystal diffraction analysis
EP2773629B1 (en) * 2011-11-01 2018-04-11 Fresenius Kabi Oncology Limited Process for the preparation of an amorphous form of cabazitaxel
DE112012004944T5 (en) * 2011-11-28 2014-12-11 Fresenius Kabi Oncology Ltd. Crystalline forms of cabazitaxel and their method of preparation
JP6025861B2 (en) * 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム Crystal form of cabazitaxel and process for preparing it
CN104220431A (en) * 2012-03-08 2014-12-17 伊瓦克斯国际有限责任公司 Solid state forms of cabazitaxel and processes for preparation thereof
CN102746258B (en) * 2012-07-25 2015-02-04 重庆泰濠制药有限公司 Crystal forms of cabazitaxel and preparation method thereof
CN104583189A (en) * 2012-07-31 2015-04-29 永信药品工业股份有限公司 Amorphous cabazitaxel
CN102898406B (en) 2012-11-02 2014-12-03 上海金和生物技术有限公司 Cabazitaxel crystal and preparation method thereof
CN103058960B (en) 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 Cabazitaxel polymorphic form and preparation method thereof

Also Published As

Publication number Publication date
EP2835369A1 (en) 2015-02-11
WO2014015760A1 (en) 2014-01-30
AU2013295924A1 (en) 2014-10-23
CA2909500C (en) 2018-01-09
CN102746258B (en) 2015-02-04
EP3067348A1 (en) 2016-09-14
US20150141674A1 (en) 2015-05-21
US9353076B2 (en) 2016-05-31
JP6329135B2 (en) 2018-05-23
JP2015518012A (en) 2015-06-25
CN102746258A (en) 2012-10-24
CA2909500A1 (en) 2014-01-30
AU2016200343B2 (en) 2017-03-30
AU2013295924B2 (en) 2016-02-18
AU2016200343A1 (en) 2016-02-11
CA2870569A1 (en) 2014-01-30
EP2835369B1 (en) 2019-04-03
EP2835369A4 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
IN2014MN01962A (en)
IN2014MN01755A (en)
PH12016500164A1 (en) Therapeutically active compounds and their methods of use
MX2020010535A (en) Methods of treating cancer.
NZ706739A (en) Substituted benzene compounds
EA201592068A1 (en) INHANSER INHIBITORS ZESTE HOMOLOGIST 2
NZ715747A (en) Syk inhibitors
NZ739760A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
IN2014MN00988A (en)
MY178621A (en) Deuterated cftr potentiators
CR20200479A (en) Therapeutically active compounds and their methods of use
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX349159B (en) Deuterated derivatives of ivacaftor.
MX2016015434A (en) Pharmaceutical combinations for treating cancer.
MX347616B (en) Csf-1r inhibitors for treatment of brain tumors.
IN2015DN01151A (en)
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
MX2014003376A (en) Benzoic acid derivatives as eif4e inhibitors.
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
MX2016003522A (en) Quinazoline derivatives and their use as dna methyltransferase inhibitors.
MX2015008187A (en) Deuterated alk inhibitors.
IN2013DN02555A (en)
WO2012112232A8 (en) METHODS AND COMPOSITIONS FOR TREATING β-THALASSEMIA AND SICKLE CELL DISEASE
IN2014DN00123A (en)
IN2015DN01329A (en)